Big Pharma CEO ratings reveal which leaders earn the highest employee approval, impacting company performance and satisfaction.
Author: PharmaSignal News Desk
Kelun Merck ADC shows promise in lung cancer treatment, succeeding in a late-stage trial with potential for first-line approval.
Bayer Asundexian trial results indicate potential for a new class of cardiovascular drugs in stroke prevention.
Novo Nordisk GLP-1 drug fails in Alzheimer’s trials, impacting potential neurodegeneration treatment.
Takeda rare disease drug is under FDA review following a patient death and reports of neutralizing antibodies.
In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, significant M&A activity, key regulatory approvals, and notable pipeline developments shaped the global pharma landscape. Meanwhile, pricing decisions and policy shifts continue to influence market dynamics and strategic positioning. M&A and Strategic Deals Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05B expands its footprint in the metabolic disease space. Read more → Biogen’s partnership with Dayra aims to enhance its immunological disease portfolio, indicating a strategic focus on immune-mediated conditions. Read more → Regulatory and Approvals Otsuka secured FDA approval for Voyxact in kidney disease, marking a significant step…
Novartis job cuts affect hundreds in Swiss manufacturing, while Novo’s diabetes drug advances to Phase 3 trials.
Otsuka FDA approval marks a first for anti-APRIL therapy targeting IgA nephropathy, impacting over 100,000 US patients.
Medicare price negotiation establishes 2027 prices for Wegovy and Trelegy, reducing spending by 44% over 2024 list prices.
Big Pharma CEO ratings reveal employee approval levels, highlighting leadership impact on companies.